The similarities between our results using panobinostat in combination with ATO in mice bearing A/E9a;NrasG12D tumors and the effects of retinoids and ATO in models of PML-RARα-driven APL indicate that, as differentiation therapy combined with ATO has been so successful in curing patients with PML, the combination of panobinostat and ATO for relapsed t(8;21) patients may have similar success. This evidence concerns the gene RARA and acute promyelocytic leukemia.